Quinapril, an angiotensin-converting enzyme (ACE) inhibitor used to treat hypertension and heart failure, was developed in the 1980s and approved for medical use in the early 1990s. Its history is marked by its effectiveness in lowering blood pressure and reducing cardiovascular risk, including prevention of stroke and heart failure progression. Quinapril works by inhibiting the ACE enzyme, which reduces the formation of angiotensin II, leading to vasodilation, decreased peripheral resistance, and improved cardiac workload.
Quinapril was introduced as part of the expanding class of ACE inhibitors and became widely used in both monotherapy and combination therapy for hypertension. It is often prescribed alongside diuretics or other antihypertensive agents to achieve better blood pressure control. Over time, it has remained an important option in cardiovascular disease management due to its efficacy and tolerability profile.
BRAND NAMES
Accupril – the main branded formulation of quinapril used for hypertension and heart failure
Accuretic – combination product containing quinapril with hydrochlorothiazide for better blood pressure control.
MECHANISM OF ACTION
Quinapril is an angiotensin-converting enzyme (ACE) inhibitor. After oral administration, it is converted in the liver to its active metabolite, quinaprilat. Quinaprilat blocks the ACE enzyme responsible for converting angiotensin I to angiotensin II. This leads to reduced levels of angiotensin II, resulting in vasodilation, decreased aldosterone secretion, reduced sodium and water retention, and ultimately lowering of blood pressure and cardiac workload.
PHARMACOKINETICS
Absorption:
Quinapril is well absorbed after oral administration, with moderate bioavailability. Food may slightly reduce absorption but does not significantly affect clinical effectiveness.
Distribution:
The active metabolite quinaprilat is distributed throughout body tissues and is moderately bound to plasma proteins.
Metabolism:
Quinapril is a prodrug that is rapidly hydrolyzed in the liver to quinaprilat, its active form.
Elimination:
Elimination occurs mainly through renal excretion of quinaprilat. The elimination half-life supports once or twice daily dosing depending on clinical condition.
PHARMACODYNAMICS
Quinapril lowers blood pressure by inhibiting the renin–angiotensin–aldosterone system (RAAS). By reducing angiotensin II levels, it causes relaxation of blood vessels and decreases peripheral vascular resistance. It also reduces aldosterone secretion, leading to decreased sodium and water retention. These combined effects improve cardiac output and reduce strain on the heart, making it useful in hypertension and heart failure management.
ADMINISTRATION
Quinapril is administered orally in tablet form. It is typically taken once or twice daily depending on the prescribed dose and patient response. It may be taken with or without food, and dosing is individualized based on blood pressure control and renal function.
DOSAGE AND STRENGTH
Quinapril is available in strengths of 5 mg, 10 mg, 20 mg, and 40 mg tablets. For hypertension, initial doses are usually low and gradually increased. Maintenance doses commonly range from 10 mg to 80 mg per day, either as a single dose or divided doses. Dose adjustments are required in patients with renal impairment.
DRUG INTERACTIONS
Quinapril may interact with potassium-sparing diuretics (such as spironolactone), potassium supplements, and other drugs that increase potassium levels, leading to hyperkalemia. Nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce its antihypertensive effect. Concomitant use with diuretics or other antihypertensives may enhance blood pressure lowering, increasing the risk of hypotension.
FOOD INTERACTIONS
Food may slightly reduce the absorption of quinapril, but this effect is not clinically significant. It can be taken with or without meals.
CONTRAINDICATIONS
Quinapril is contraindicated in patients with a history of angioedema related to ACE inhibitor therapy, during pregnancy, and in individuals with hypersensitivity to quinapril or other ACE inhibitors. It should also be avoided in patients with severe renal artery stenosis.
SIDE EFFECTS
Dry cough
Dizziness
Headache
Hypotension
Fatigue
Elevated potassium levels (hyperkalemia)
TOXICITY
Quinapril overdose may lead to severe hypotension, electrolyte imbalance, bradycardia, and kidney impairment. Management is mainly supportive, including intravenous fluids, monitoring of blood pressure, and correction of electrolyte disturbances. Hemodialysis may help remove active metabolites in severe cases.
